非梗阻性肥厚型心肌病不同临床亚型的临床与遗传学特征
该队列研究纳入1999至2019年阜外医院815例非梗阻性HCM患者,分为普通型、扩张型、限制型和射血分数降低型。各亚型基因突变谱相似,但限制型肌小节突变比例更高、射血分数降低型多突变比例更高;限制型、扩张型和射血分数降低型心血管死亡风险均显著高于普通型。
要点
- 非梗阻性HCM中普通型占86.7%,临床表现轻且预后良好。
- 限制型、扩张型虽收缩功能多保留,但心血管死亡风险显著高于普通型。
- 限制型肌小节突变比例更高,射血分数降低型多突变比例更高。
核心结论
- 非梗阻性HCM大多数为普通型,临床表型轻且预后良好。
- 限制型和扩张型虽占比较低且收缩功能多保留,但临床表型和预后与射血分数降低型一样严重。
- 各临床亚型突变基因类型相似,但限制型肌小节突变比例更高,射血分数降低型多突变比例更高。
研究设计与样本
- 队列研究,纳入1999年1月至2019年4月中国医学科学院阜外医院非梗阻性HCM患者815例。
- 根据超声心动图心脏形态及功能分为普通型、扩张型、限制型及射血分数降低型。
- 应用全外显子测序或Panel测序筛查8个肌小节致病基因,随访记录心血管死亡终点事件。
主要发现
- 815例中限制型27例(3.3%)、扩张型51例(6.3%)、射血分数降低型30例(3.7%)、普通型707例(86.7%)。
- 704例基因检测患者中299例(42.5%)携带至少1个肌小节基因致病突变,MYBPC3占42.1%(126/299),MYH7占35.8%(107/299)。
- 限制型66.7%(16/24)携带肌小节突变,高于扩张型36.4%(16/44)和普通型41.5%(250/602),P=0.015。
- 射血分数降低型56.7%(17/30)携带肌小节突变,23.3%(7/30)携带多个肌小节突变,高于限制型8.3%(2/24)、扩张型9.1%(4/44)和普通型4.2%(24/577),P<0.001。
- 随访703例,中位2.9(1.4,4.0)年,心血管死亡53例(7.5%);普通型5.0%(29/578)、限制型13.0%(3/23)、扩张型16.3%(7/43)、射血分数降低型46.7%(14/30)。
关键数值与推荐
- 多因素Cox校正性别、发病年龄、体重指数、高血压病史、冠心病病史、糖尿病病史后,限制型心血管死亡HR=5.454(95%CI 1.137~26.157,P=0.034)。
- 扩张型心血管死亡HR=6.597(95%CI 1.632~26.667,P=0.008)。
- 射血分数降低型心血管死亡HR=9.028(95%CI 2.201~37.039,P=0.002)。
- 各临床亚型突变基因均以MYH7及MYBPC3为主,组间差异无统计学意义(P均>0.05)。
临床怎么用
- 对非梗阻性HCM应进行临床亚型分型,限制型、扩张型和射血分数降低型需加强风险评估与随访。
- 限制型患者应关注肌小节基因突变检测,射血分数降低型患者应关注多突变筛查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the clinical and genetic characteristics of clinical subtypes of non-obstructive hypertrophic cardiomyopathy (HCM). Methods: It was a cohort study. Patients with non-obstructive HCM admitted to Fuwai Hospital, Chinese Academy of Medical Sciences, from January 1999 to April 2019 were enrolled. According to the characteristics of cardiac morphology and function shown by echocardiography, the patients were divided into common type, dilated type, restricted type and reduced ejection fraction type. The clinical data of the patients were recorded, and 8 sarcomere pathogenic genes were screened by full exon sequencing or panel sequencing. Patienst were followed up and cardiovascular endpoint events were recorded. Results: A total of 815 patients with non-obstructive HCM were enrolled, including 27 (3.3%) restricted type, 51 (6.3%) dilated type, 30 (3.7%) reduced ejection fraction type and 707 (86.7%) common type. A total of 704 out of 815 patients underwent genetic testing. Among them, 299 (42.5%) patients carried at least 1 sarcomere gene mutation. MYBPC3 and MYH7 mutation accounted for 42.1% (126/299) and 35.8% (107/299) respectively. 66.7% (16/24) of the patients with restricted type carried sarcomere gene mutation, which was higher than that in patients with dilated type (36.4% (16/44)) and in common type (41.5% (250/602), P=0.015). Among the patients with reduced ejection fraction, 56.7% (17/30) patients carried sarcomere gene mutations, 23.3% (7/30) carried multiple sarcomere mutations, which was higher than that in restricted type (8.3% (2/24)), in dilated type (9.1% (4/44)) and in common type 4.2% ((24/577), P<0.001). MYH7 and MYBPC3 were the main mutation gene types of all clinical subtypes, and the genotypes were similar among groups (all P>0.05). Seven hundred and three out 815 patients were followed up for 2.9 (1.4, 4.0) years. There were 53(7.5%) cardiovascular death. Cardiovascular death occurred in 5.0% (29/578) patients with common type, 13.0% (3/23) patients with restricted type, 16.3% (7/43) patients with dilated type and 46.7% (14/30) patients with decreased ejection fraction. Univariate Cox proportional hazards model analysis showed that the risk of cardiovascular death in patients with restricted, dilated and reduced ejection fraction type was higher than that in patients with common type (P<0.001). After adjusting for gender, age of onset, body mass index, history of hypertension, coronary heart disease and diabetes, multivariate Cox proportional hazards model analysis showed that the HR of cardiovascular death in patients with restricted, dilated and reduced ejection fraction type were 5.454 (95%CI 1.137-26.157, P=0.034) and 6.597 (95%CI 1.632-26.667, P=0.008) and 9.028 (95%CI 2.201-37.039, P=0.002) respectively, as compared to patients with common type. Conclusions: Most of the patients with non-obstructive HCM are common type, featured by mild clinical manifestations and good prognosis. Although the proportion of restricted type and dilated type is relatively low, and cardiac systolic function is mostly preserved, the clinical phenotype and prognosis of these patients are similarly severe and poor as patients with reduced ejection fraction. The genotypes are similar in different clinical subtypes, but the proportion of patients with sarcomere gene mutation is higher in restricted type, and the proportion of patients with multiple sarcomere gene mutation is higher in decreased ejection fraction type. 目的: 分析非梗阻性肥厚型心肌病(HCM)各临床亚型的临床及遗传学特征。 方法: 该研究为队列研究。入选1999年1月至2019年4月在中国医学科学院阜外医院就诊的非梗阻性HCM患者。根据超声心动图所示心脏形态及功能特点将入选患者分为普通型、扩张型、限制型及射血分数降低型。记录入选患者的临床资料,并应用全外显子测序或Panel测序筛查8个肌小节致病基因。随访并记录心血管死亡终点事件。 结果: 共入选非梗阻性HCM患者815例,其中限制型27例(3.3%),扩张型51例(6.3%),射血分数降低型30例(3.7%),普通型707例(86.7%)。815例患者中共704例进行了基因检测,其中299例(42.5%)患者携带至少1个肌小节基因致病突变,MYBPC3和MYH7分别占42.1%(126/299)和35.8%(107/299)。限制型的患者中66.7%(16/24)携带肌小节基因致病突变,较扩张型的36.4%(16/44)及普通型的41.5%(250/602)高(P均<0.05)。射血分数降低型患者中56.7%(17/30)携带肌小节基因致病突变,23.3%(7/30)携带多个肌小节突变,较限制型的8.3%(2/24)、扩张型的9.1%(4/44)及普通型的4.2%(24/577)更高(P均<0.001)。各临床亚型患者携带的突变基因类型均以MYH7及MYBPC3为主,各分型间差异无统计学意义(P均>0.05)。对815例患者中的703例进行了随访,随访时间2.9(1.4,4.0)年,共53例(7.5%)患者发生心血管死亡终点事件。普通型患者中5.0%(29/578)发生心血管死亡,限制型患者中13.0%(3/23)发生心血管死亡,扩张型患者中16.3%(7/43)发生心血管死亡,射血分数降低型患者中46.7%(14/30)发生心血管死亡。单因素Cox比例风险模型分析结果显示,限制型、扩张型及射血分数降低型患者的心血管死亡风险均高于普通型(P<0.001),但三种类型之间差异无统计学意义。多因素Cox比例风险模型分析结果显示,校正了性别、发病年龄、体重指数、高血压病史、冠心病病史、糖尿病病史后,限制型、扩张型和射血分数降低型患者心血管死亡风险相对于普通型的HR分别为5.454(95%CI 1.137~26.157,P=0.034)、6.597(95%CI 1.632~26.667,P=0.008)和9.028(95%CI 2.201~37.039,P=0.002)。 结论: 非梗阻性HCM患者大多数为普通型,临床表现轻且预后良好,而限制型、扩张型虽占比较低且未出现心脏收缩功能降低,但与射血分数降低型一样临床表型均可较为严重、预后不佳。各临床亚型患者携带突变基因类型虽无差异,但限制型患者携带肌小节突变比例更高,射血分数降低型患者携带多个肌小节突变比例较高。.
引用
- Zhang M, Sun XL, Wu GX, et al. [Clinical and genetic characteristics of different types of non-obstructive hypertrophic cardiomyopathy]. Zhonghua Xin Xue Guan Bing Za Zhi. 2021. PMID: 34126727. doi:10.3760/cma.j.cn112148-20210118-00056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。